Business Briefing: F.D.A. Clears Cheaper Version of Johnson & Johnson Biologic

Business Briefing: F.D.A. Clears Cheaper Version of Johnson & Johnson Biologic

Federal officials have approved a cheaper version of Johnson & Johnson’s blockbuster drug Remicade, a biotech medicine for inflammatory diseases.

Read More…